Qrons Inc., a biotechnology company focused on combating neuronal and infectious diseases, has announced the addition of Professor Shiri Navon-Venezia to its Scientific Advisory Board. Professor Navon-Venezia, a distinguished expert in Microbiology and Head of Bacterial Pathogens & Antibiotic Resistance Lab at Ariel University, brings her extensive knowledge and expertise in antibiotic resistance, bacterial pathogenesis, and drug development to Qrons Inc.
Antimicrobial resistance remains a pressing global public health threat, causing millions of deaths each year. With over 100 articles published and a career dotted with awards and citations, Professor Navon-Venezia’s addition to the Scientific Advisory Board will play a crucial role in shaping Qrons’ research program. The company aims to utilize certain Tellurium-based compounds to combat antibiotic-resistant bacterial infections, including Sepsis, a life-threatening medical emergency associated with high mortality rates.
Sepsis affects millions of individuals annually, and a significant percentage of patients who develop sepsis do not survive their hospitalization. Qrons Inc. recognizes the urgency to address these issues and is committed to developing innovative products, treatments, and technologies to combat neuronal diseases and infectious diseases caused by antibiotic-resistant bacteria.
Qrons Inc., headquartered in New York City with research centered in Israel, seeks to establish strategic partnerships with universities, companies, and scientists actively engaged in stem cell research, antibiotic-resistant drug development, and tissue engineering. This collaborative approach enables Qrons to deploy unique intellectual properties and expertise in their fight against neuronal and infectious diseases.
As an innovative biotechnology company, Qrons Inc. is dedicated to making significant contributions to the field of microbiology and antibiotic research. The addition of Professor Shiri Navon-Venezia to its Scientific Advisory Board strengthens the company’s expertise, positioning them at the forefront of cutting-edge research and development.
Frequently Asked Questions (FAQ)
1. What is Qrons Inc.?
Qrons Inc. is a biotechnology company based in New York City, focused on developing products, treatments, and technologies to combat neuronal and infectious diseases. Their research is centered in Israel, and they actively seek strategic partnerships with universities and organizations involved in stem cell research, antibiotic-resistant drug development, and tissue engineering.
2. Who is Professor Shiri Navon-Venezia?
Professor Shiri Navon-Venezia is a renowned expert in Microbiology and the Head of Bacterial Pathogens & Antibiotic Resistance Lab at Ariel University. With a distinguished career, she specializes in the pathogenesis of multidrug-resistant bacteria, molecular mechanisms of antibiotic resistance, genetic elements, and their role in bacterial resistance and pathogenesis. Professor Navon-Venezia has authored over 100 articles and is a member of prominent microbiology societies.
3. What is antimicrobial resistance?
Antimicrobial resistance refers to the ability of microorganisms, such as bacteria, viruses, parasites, and fungi, to withstand the effects of antimicrobial drugs. It is a global public health threat, leading to severe infections that are difficult to treat and causing millions of deaths annually.
4. What is Sepsis?
Sepsis is a life-threatening medical condition characterized by the body’s extreme response to an infection. It can lead to organ failure and death. Each year, millions of individuals develop sepsis, and it is a significant cause of mortality in hospitals.
5. How does Qrons Inc. aim to combat antibiotic-resistant bacterial infections?
Qrons Inc. plans to utilize certain Tellurium-based compounds in their research to address antibiotic-resistant bacterial infections. By leveraging the expertise of their Scientific Advisory Board, including Professor Shiri Navon-Venezia, Qrons aims to develop innovative therapeutics that can effectively combat these infections and improve patient outcomes.